November 07, 2026

The Manager- Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing
National Stock Exchange of India Limited
Exchange Plaza,
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir/ Madam,

Subject: Launch of Datopotamab Deruxtecan (Brand name: Datverzo)

We refer to our earlier communication dated 17th December, 2025 intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Datopotamab Deruxtecan (Brand name: Datverzo).

With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited will launch Datverzo in India in November 2026.

Datverzo is already approved for treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease iu adults with HR+/HER2– mBC.

We request you to take the above intimation on record.

Thanking you,

For **AstraZeneca Pharma India Limited**

TANYA SANISH
Digitally signed by TANYA SANISH
Date: 2026.11.07 12:03:31 +05'30'

Tanya Sanish
Company Secretary & Compliance Officer
ACS No.: A25784

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628